Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. reported a net loss of $21.8 million for fiscal year 2025, an improvement from a $44.6 million net loss in 2024. The company's operating expenses decreased significantly to $23.0 million from $51.8 million in the prior year, driven by a 56% reduction in research and development costs to $11.5 million and a 55% reduction in general and administrative expenses to $11.5 million. Cash used in operating activities was $23.1 million, while financing activities provided $13.0 million in cash from warrant exercises and stock issuances. As of December 31, 2025, the company had $13.2 million in cash and cash equivalents, with management noting substantial doubt about the company's ability to continue as a going concern beyond the third quarter of 2026 without additional funding or strategic transactions.

Key Takeaways